Resonant Sensors

Executive Summary

Resonant Sensors is a US-based medical device and diagnostics company founded in 2016 that has developed the ResoSens platform, a semi-automated, label-free benchtop system leveraging guided-mode resonance (GMR) biosensor technology. The platform enables high-throughput, real-time kinetic analysis of biomolecular interactions in a standard 96-well plate format, addressing a critical bottleneck in antibody discovery and characterization. By eliminating the need for labels and reducing manual steps, ResoSens accelerates early-stage drug development, offering pharmaceutical and biotechnology researchers a faster, more efficient tool for screening and characterizing therapeutic candidates. The technology is particularly valuable for identifying high-affinity antibodies and understanding binding kinetics, which are essential for successful drug development. Resonant Sensors competes in the growing label-free biosensor market, which is driven by increasing demand for high-throughput, real-time analysis in drug discovery. The company's key differentiators include its semi-automated workflow and compatibility with existing 96-well plate formats, lowering barriers to adoption. While still in early commercialization, Resonant Sensors has the potential to capture market share from established platforms like Biacore by offering a more cost-effective and scalable solution. Key near-term milestones include securing strategic partnerships with major pharmaceutical companies and closing initial funding rounds to scale production and expand sales. If successful, the company could become a key enabler of faster antibody-based drug discovery.

Upcoming Catalysts (preview)

• Q4 2026Strategic Partnership with Top 20 Pharma45% success
• Q2 2027Series A Funding Round70% success
• Q3 2026First Commercial Sale or Beta Launch60% success